Saturday 17 October 2026
Export ACGN’s income statement to Excel — free account
Aceragen, Inc.
ACGN Healthcare Biotechnology
Aceragen, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $4.9 million. Operating cash flow growth for five consecutive years.
Follow ACGN
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | Trend | 2023e | 2024e | 2025e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2023–2025 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | — | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 62 | 62 | 36 | 36 | 32 | 13 | 12 | ||||
| Revenue/emp, $m | — | — | — | 0.26 | 0.01 | 0.02 | 0.04 | 0.00 | 0.00 | 0.41 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | 16 | 1 | 1 | 1 | — | — | 5 | ||||
| Gross margin, % | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 0.00 | 0.00 | 100.00 | |||||
| EBT | — | — | — | (38) | (66) | (60) | (57) | (113) | 98 | (30) | |||||
| EBT margin, % | — | — | — | (236.98) | (7,315.30) | (9,045.47) | (3,902.97) | 0.00 | 0.00 | (610.41) | |||||
| Net income | — | — | — | (38) | (66) | (60) | (57) | (113) | 98 | (23) | |||||
| Depreciation | — | — | — | 1 | 1 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 17.27 | 0.78 | 0.42 | 0.86 | 0.00 | 0.00 | 1.49 | ||||
| Earnings | — | — | — | (40.82) | (57.14) | (38.26) | (50.34) | (56.63) | 33.50 | (7.18) | |||||
| Cash flow | — | — | — | (30.07) | (47.76) | (33.19) | (26.51) | (16.98) | (8.50) | (7.52) | |||||
| Capex | — | — | — | (0.43) | (0.18) | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (30.51) | (47.94) | (33.05) | (26.51) | (16.99) | (8.50) | (7.52) | |||||
| Book value | — | — | — | 110.19 | 93.09 | 40.91 | (6.65) | (45.84) | 10.18 | 11.96 | |||||
| Shares, m | — | — | — | 1 | 1 | 2 | 2 | 2 | 3 | 3 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | ||||
| P/S | — | — | — | 11.81 | 385.50 | 111.26 | 27.99 | — | — | 3.98 | |||||
| P/B | — | — | — | 1.85 | 3.23 | 1.15 | 0.00 | — | — | 2.16 | |||||
| EV/Sales | — | — | — | 5.11 | 260.99 | 3.85 | 5.50 | — | — | 6.55 | |||||
| EV/FCF | — | — | — | (2.89) | (4.24) | (0.05) | (0.23) | — | — | (1.71) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (28) | (55) | (52) | (44) | (34) | (25) | (24) | ||||
| Capex | — | — | — | 0 | 0 | 0 | 0 | 0 | — | — | |||||
| Free cash flow | — | — | — | (29) | (55) | (52) | (44) | (34) | (25) | (24) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 102 | 107 | 64 | (8) | 34 | 29 | (4) | ||||
| Total debt | — | — | — | 0 | 0 | — | 1 | 1 | 1 | — | |||||
| Net debt | — | — | — | (109) | (113) | (71) | (43) | (38) | (33) | (12) | |||||
| Shareholders’ equity | — | — | — | 103 | 108 | 64 | (11) | (91) | 29 | 39 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (37.36) | (56.97) | (62.56) | (140.33) | (250.67) | 250.94 | (34.36) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (64.66) | |||||
| ROE | — | — | — | (41.07) | (62.53) | (69.76) | (320.14) | 220.17 | (314.14) | (113.18) | |||||
Negative figures in brackets.
Fiscal years to Dec 2022 · latest quarter Mar 2023
Charts ten years each
Aceragen, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ATYR aTyr Pharma, Inc. | $18.0M | — (loss-making) | — (loss-making) | −90.75% (below 0%: shrinking) | n/m | +32.22% (above 0%: growing) | 100.00% | 0.00% | Compare |
| NEUP Neuphoria Therapeutics Inc. | $17.9M | — (loss-making) | — (loss-making) | −107.32% (below 0%: shrinking) | n/m | +133.86% (above 0%: growing) | 100.00% | 0.00% | Compare |
| JSPR Jasper Therapeutics, Inc. | $17.7M | — (loss-making) | — | — | n/m | +55.74% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ANEB Anebulo Pharmaceuticals, Inc. | $17.6M | — (loss-making) | — | — | n/m | +6.58% (above 0%: growing) | — | 0.00% | Compare |
| ACGN Aceragen, Inc. | $17.1M | — (loss-making) | — (loss-making) | +2,394.95% (above 0%: growing) | n/m | −115.67% (below 0%: shrinking) | 100.00% | (834.33%) | |
| RADX Radiopharm Theranostics Limited - Sponsored ADR | $17.0M | — | — | — | — | −137.75% (below 0%: shrinking) | — | — | Compare |
| DYAI Dyadic International Inc. | $16.8M | — (loss-making) | — (loss-making) | −0.57% (below 0%: shrinking) | n/m | −1,298.54% (below 0%: shrinking) | (2.39%) | (213.73%) | Compare |
| PBM Psyence Biomedical Ltd. | $16.5M | 0.2× | — | — | n/m | −707.20% (below 0%: shrinking) | — | 0.00% | Compare |
| TCRX TScan Therapeutics, Inc. | $16.2M | — (loss-making) | — (loss-making) | −65.83% (below 0%: shrinking) | n/m | +18.95% (above 0%: growing) | 100.00% | (2,901.33%) | Compare |
| Median of peers | $17.3M | — | — | −78.29% | — | +12.76% | 100.00% | 0.00% |
Aceragen, Inc. (ACGN) key facts
- Aceragen, Inc. (ACGN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Aceragen, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $4.9 million.
- Return on equity was −113.2% and debt-to-equity 0.00.
Aceragen, Inc. (ACGN) Latest News
No news at this impact. Lower the threshold for more.